Vital Patch secures FDA Emergency Use Authorization for cardiac monitoring in COVID- 19 patients.- VitalConnect

VitalConnect announced that it has received FDA Emergency Use Authorization status for use of its VitalPatch to detect changes in the QT interval of hospitalized patients undergoing drug treatment for COVID-19. Hydroxychloroquine and chloroquine, used to treat some COVID-19 patients, are associated with risk of prolonged QT interval that can lead to life-threatening arrhythmias. VitalPatch allows clinicians to remotely and continuously monitor patients at risk of QT prolongation due to COVID-19 treatment. VitalPatch is an FDA-approved device. It serves as a single-lead ECG, and monitors seven other physiological parameters continuously, including body temperature, heart rate, heart rate variability, respiratory rate, and blood oxygen saturation levels.